sulfasalazine has been researched along with Edema-Proteinuria-Hypertension Gestosis in 9 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sulfasalazine was not able to rescue fetal growth, in male or female fetuses." | 5.91 | Sulfasalazine for the treatment of preeclampsia in a nitric oxide synthase antagonist mouse model. ( Beard, S; Binder, NK; Brownfoot, FC; de Alwis, N; Hannan, NJ; Harper, A; Kadife, E; Kaitu'u-Lino, TJ, 2023) |
| "Sulfasalazine has been identified as a candidate molecule to be investigated as an intervention to treat preterm pre-eclampsia during pregnancy." | 4.31 | An LC-MS/MS method for the simultaneous quantitation of sulfasalazine and sulfapyridine in human placenta. ( Brownfoot, F; Cluver, C; Decloedt, E; Kellermann, T; Louw, V, 2023) |
| "We performed functional experiments using primary human pregnancy tissues to examine the effects of sulfasalazine on sFlt-1, sENG and PlGF secretion." | 3.91 | Sulfasalazine reduces placental secretion of antiangiogenic factors, up-regulates the secretion of placental growth factor and rescues endothelial dysfunction. ( Brownfoot, FC; Cannon, P; Hannan, NJ; Hastie, R; Kaitu'u-Lino, TJ; Nguyen, V; Parry, LJ; Senadheera, S; Tong, S; Tuohey, L, 2019) |
| "Sulfasalazine was not able to rescue fetal growth, in male or female fetuses." | 1.91 | Sulfasalazine for the treatment of preeclampsia in a nitric oxide synthase antagonist mouse model. ( Beard, S; Binder, NK; Brownfoot, FC; de Alwis, N; Hannan, NJ; Harper, A; Kadife, E; Kaitu'u-Lino, TJ, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 7 (77.78) | 2.80 |
| Authors | Studies |
|---|---|
| Deng, Z | 1 |
| Lu, D | 1 |
| Binder, NK | 2 |
| de Alwis, N | 1 |
| Beard, S | 2 |
| Kadife, E | 1 |
| Harper, A | 1 |
| Kaitu'u-Lino, TJ | 5 |
| Brownfoot, FC | 4 |
| Hannan, NJ | 4 |
| Louw, V | 1 |
| Brownfoot, F | 2 |
| Cluver, C | 3 |
| Decloedt, E | 1 |
| Kellermann, T | 1 |
| Hastie, R | 3 |
| Cannon, P | 3 |
| Nguyen, TV | 2 |
| Tuohey, L | 2 |
| Tong, S | 4 |
| Hannan, N | 1 |
| Neuman, RI | 1 |
| Smeele, HTW | 1 |
| Jan Danser, AH | 1 |
| Dolhain, RJEM | 1 |
| Visser, W | 1 |
| Nguyen, V | 1 |
| Parry, LJ | 1 |
| Senadheera, S | 1 |
| Golding, A | 1 |
| Haque, UJ | 1 |
| Giles, JT | 1 |
2 reviews available for sulfasalazine and Edema-Proteinuria-Hypertension Gestosis
| Article | Year |
|---|---|
Pravastatin, proton-pump inhibitors, metformin, micronutrients, and biologics: new horizons for the prevention or treatment of preeclampsia.
Topics: Antibodies, Monoclonal; Antioxidants; Antithrombin III; Biological Products; Blood Component Removal | 2022 |
Rheumatoid arthritis and reproduction.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Hydroxychloroquine; Immunosuppre | 2007 |
7 other studies available for sulfasalazine and Edema-Proteinuria-Hypertension Gestosis
| Article | Year |
|---|---|
Letter by Lu et al. regarding article, "Esomeprazole and sulfasalazine in combination additively reduce sFlt-1 secretion and diminish endothelial dysfunction: potential for a combination treatment for preeclampsia".
Topics: Esomeprazole; Female; Humans; Placenta; Pre-Eclampsia; Pregnancy; Sulfasalazine; Vascular Endothelia | 2022 |
Sulfasalazine for the treatment of preeclampsia in a nitric oxide synthase antagonist mouse model.
Topics: Animals; Blood Pressure; Disease Models, Animal; Female; Humans; Hypertension; Male; Mice; Nitric Ox | 2023 |
An LC-MS/MS method for the simultaneous quantitation of sulfasalazine and sulfapyridine in human placenta.
Topics: Chromatography, Liquid; Female; Humans; Infant, Newborn; Methanol; Placenta; Pre-Eclampsia; Pregnanc | 2023 |
Combining metformin and sulfasalazine additively reduces the secretion of antiangiogenic factors from the placenta: Implications for the treatment of preeclampsia.
Topics: Drug Therapy, Combination; Endoglin; Endothelin-1; Female; Humans; Metformin; Placenta; Placenta Gro | 2020 |
Esomeprazole and sulfasalazine in combination additively reduce sFlt-1 secretion and diminish endothelial dysfunction: potential for a combination treatment for preeclampsia.
Topics: Case-Control Studies; Drug Therapy, Combination; Esomeprazole; Female; Human Umbilical Vein Endothel | 2020 |
The sFlt-1 to PlGF ratio in pregnant women with rheumatoid arthritis: impact of disease activity and sulfasalazine use.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Female; Humans; Membrane Proteins; P | 2022 |
Sulfasalazine reduces placental secretion of antiangiogenic factors, up-regulates the secretion of placental growth factor and rescues endothelial dysfunction.
Topics: Cell Movement; Cell Proliferation; Endoglin; Female; Heme Oxygenase-1; Human Umbilical Vein Endothel | 2019 |